Senisca develops RNA senotherapeutics that target dysregulated RNA splicing, a newly identified hallmark of aging that contributes to cellular senescence and age-related diseases. By restoring splicing factor levels in senescent cells, Senisca aims to reverse the detrimental effects of aging on cellular health and improve tissue function.
Funding
$10.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cellular senescence, a key hallmark of aging, contributes to age-related diseases through the accumulation of senescent cells in tissues and organs. Dysregulation of RNA splicing, a newly identified hallmark of aging, is a fundamental contributor to cellular senescence.
Solution
Senisca is developing RNA-based senotherapeutics that target dysregulated RNA splicing to reverse cellular senescence and treat age-related diseases. Their approach focuses on restoring splicing factor levels in senescent cells, thereby reprogramming them and attenuating their deleterious functions. By modulating RNA biology, Senisca aims to address the underlying causes of age-related diseases rather than merely treating the symptoms. Their oligonucleotide-based therapeutics are designed to reset splicing factor levels, effectively turning back the aging clock in senescent cells.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases, as well as pharmaceutical companies seeking innovative therapeutics in the longevity space.
Features
- Oligonucleotide-based therapeutics designed to modulate RNA splicing.
- Focus on restoring splicing factor levels in senescent cells.
- Targets a novel, druggable hallmark of aging: dysregulated RNA splicing.
- Aims to reprogram senescent cells and attenuate their deleterious functions.
- Therapeutic approach targets the causes, not just the consequences, of age-related disease.